Rising Prevalence Of Chronic Diseases Fueling The Growth Of The Market Due To Increasing Demand For Targeted Therapies Is Supporting Development Across The Biologics Manufacturing Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Biologics Manufacturing Market During The 2026–2030 Period?

The biologics manufacturing market has experienced substantial growth in recent years. Its valuation is anticipated to climb from $42.04 billion in 2025 to $50.69 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.6%. Several factors contributed to this historic expansion, including the spread of recombinant protein therapeutics, the early implementation of mammalian cell culture systems, an uptick in vaccine manufacturing capacity, the growing trend of outsourcing biologics production, and developments in purification technologies.

The biologics manufacturing market size is projected to experience rapid expansion over the upcoming years. Its value is anticipated to reach $106.08 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 20.3%. This projected growth during the forecast period stems from factors such as the escalating demand for customized biologics, increased capital allocation towards adaptable manufacturing setups, the broadening scope of biosimilar creation, the expanding use of digital bioprocessing instruments, and an emphasis on economical, high-volume production. Key trends anticipated within the same period encompass the wider acceptance of single-use bioprocessing technologies, the increasing implementation of continuous biomanufacturing methods, a surging need for substantial quantities of monoclonal antibodies, the development of modular biologics plants, and improved incorporation of sophisticated process control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30212&type=smp

What Major Growth Factors Are Impacting The Biologics Manufacturing Market?

An escalating occurrence of chronic illnesses is anticipated to fuel the expansion of the biologics manufacturing market moving ahead. These are enduring health conditions that manifest gradually and persist over long durations, frequently necessitating ongoing medical attention. The growing prevalence of chronic diseases is partly attributable to sedentary lifestyles, given that extended periods of sitting and insufficient physical exercise elevate the likelihood of developing conditions like heart disease and diabetes. Biologics manufacturing improves the management of chronic illnesses through the creation of specific therapies, which are effective for ailments including diabetes, cancer, and various autoimmune conditions. This manufacturing process lessens the impact of disease by supplying reliable, superior biologic medications, thereby enhancing patient results and the effectiveness of treatment. As an illustration, data from June 2024 by the National Health Service, a UK government body, indicated that 3,615,330 individuals registered with a general practitioner (GP) received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a state of heightened blood sugar levels, insufficient to be classified as diabetes) in 2023. This represented an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the increasing incidence of chronic illnesses is propelling the expansion of the biologics manufacturing market.

Which Segment Groups Define The Biologics Manufacturing Market Landscape?

The biologics manufacturing market covered in this report is segmented –

1) By Mode of Manufacturing: Contract Manufacturing, In-House Manufacturing

2) By Modality: Monoclonal Antibodies (mAbs), Biosimilar And Recombinant Proteins, Vaccines (recombinant/mRNA/Viral), Cell And Gene Therapies, Ribonucleic Acid-Based Therapeutics

3) By Disease Indication: Oncology, Autoimmune Disorders, Infectious Diseases, Neurological Disorders, Other Disease Indications

Subsegments:

1) By Contract Manufacturing: Mammalian Cell-Based Production, Microbial Fermentation Production, Cell-Free Protein Synthesis, Hybrid Manufacturing Systems

2) By In-House Manufacturing: Mammalian Cell Culture Production, Microbial Expression Systems, Continuous Bioprocessing, Single-Use Technology Production

What Trends Are Impacting The Biologics Manufacturing Market?

Leading companies operating in the biologics manufacturing market are concentrating on developing advanced solutions, such as integrated biologics contract development and manufacturing organization platforms. These efforts aim to improve end-to-end biologics development, boost production efficiency, and streamline supply chain integration across numerous therapeutic modalities. An integrated biologics contract development and manufacturing organization (CDMO) platform is defined as a comprehensive framework that unifies biologics development, production, and supply services into a single, cohesive system. For instance, in June 2023, Catalent Inc., a US-based contract development and manufacturing company, broadened its OneBio Suite for integrated development, manufacturing, and supply across biologic modalities. The enhanced OneBio Suite now offers a fully integrated biologics Contract Development and Manufacturing Organization (CDMO) platform that supports antibodies, cell and gene therapies, and mRNA-based products. This platform delivers comprehensive services, from initial development to fill-finish and packaging, all managed under a single contract and coordinated project management, which facilitates quicker development timelines, enhanced scalability, and seamless global supply integration.

Who Are The Prominent Players Across The Biologics Manufacturing Market?

Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE

Access The Complete Biologics Manufacturing Market Report:

https://www.thebusinessresearchcompany.com/report/global-biologics-manufacturing-market-report

Which Region Holds The Largest Share In The Biologics Manufacturing Market?

North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biologics Manufacturing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30212&type=smp

Browse Through More Reports Similar to the Global Biologics Manufacturing Market 2026, By The Business Research Company

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Biologics Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795